OpenAI buys Orchestra Bio to add drug-discovery agents to its Rosalind life sciences work

Orchestra builds AI agents that help biotech companies run drug-discovery operations, from tracking finances to resolving clinical trial scheduling conflicts. OpenAI says it is adding the startup's team and technology to Rosalind, its AI model for life sciences research, and to Rosalind Workbench, a tool for planning experiments and analyzing results. The deal was announced on Tuesday, October 20. OpenAI did not disclose the price. The startup had earlier backing from Andreessen Horowitz, Atria and 8VC. For founders, the signal is that frontier labs are buying workflow-specific startups instead of only shipping general models. Vertical AI companies in regulated fields such as clinical operations should expect labs to compete directly on the same tasks, so the defensible layer is likely the data, integrations and domain process rather than the agent itself.